AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 141 min read$IPSC

Century Therapeutics (NASDAQ: IPSC) officer lines up 1,658-share stock sale

Century Therapeutics officer Douglas Carr filed a Rule 144 notice to sell 1,658 shares, valued at $3,200.77, including shares to cover tax obligations. The shares vest on September 11, 2026, as part of his compensation. Carr previously sold 275 and 254 shares in August and September 2026, respectively.

Original reporting
stocktitan.net
Published Sep 14, 2026, 7:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$IPSC
Neutral
high confidence
Mentioned
$IPSC
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$IPSCNeutralLow
01

Why it matters

The disclosed sale is minor and unlikely to affect market perception of Century Therapeutics.

02

Market read

Low relevance; routine insider sale with negligible price impact.

03

What to watch

Potential tax-driven timing; no strategic implication for the company.

Relevance 4/10Novelty 2/10Timing: today

Background

Form 4 filings disclose insider transactions; traders watch for material changes in insider holdings.

Company-level read

Ticker impact

$IPSCNeutralHigh confidence
Context

Officer Douglas Carr filed a Form 4 to sell up to 1,658 shares of Century Therapeutics (IPSC) for an estimated $3,200.77.

Expected impact

minimal or no impact

Evidence & confidence

Sale size is trivial relative to market cap; no broader market implications.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal confidence issues; monitor for further disposals.

Key entities

  • company
    Century Therapeutics

    Biotech firm listed on NASDAQ under ticker IPSC.

  • insider
    Douglas Carr

    Officer of Century Therapeutics filing the sale.

Read at source← All news

Related articles

OCT 2
$IPSCMedAI 8/10

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026 Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Centur

SEC EDGAR 8-K2 min
OCT 2
$IPSCMedAI 8/10

Century Therapeutics presents diabetes therapy data at EASD

Century Therapeutics (NASDAQ:IPSC) presented data on CNTY-813, a diabetes therapy, at the EASD meeting. The therapy showed long-term glycemic control in mouse models and successful engraftment in rats. The company plans to submit an IND application in Q4 2026, with clinical data expected in H2 2027, according to the press release.

investing.com2 min
OCT 2
$IPSCMed

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics (NASDAQ: IPSC) presented nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at EASD 2026. Data showed glycemic control in diabetic mice, scalable production, and immune evasion. The company expects to submit an IND application in Q4 2026 and anticipates initial clinical data in 2H 2027.

globenewswire.com3 min
AUG 18
$IPSCHighAI 8/10

Century Targets FDA Filing for Diabetes Cell Therapy

Century Therapeutics (NASDAQ: IPSC) aims to file for FDA approval of its diabetes cell therapy, CNTY-813, in Q4 2026, with initial human data expected in 2027. The company reported $197.2M in cash as of Q2 2026, sufficient to fund operations into Q1 2029. Preclinical results showed promising glucose control and immune evasion, but clinical outcomes are not guaranteed. Century also advances CNTY-308, a CAR-iT cell therapy, with IND-enabling work on track for 2026. Q2 R&D expenses decreased 27% to

mychesco.com3 min